<DOC>
	<DOC>NCT01418274</DOC>
	<brief_summary>This single-arm, open-label, non-randomized study will evaluate the effect of danoprevir/ritonavir on the pharmacokinetics of escitalopram and S-demethylcitalopram in healthy volunteers. Healthy volunteers will receive oral doses of danoprevir/ritonavir and escitalopram. The anticipated time of the study is 6 weeks.</brief_summary>
	<brief_title>A Study to Evaluate the Effect of Danoprevir/Ritonavir on the Pharmacokinetics of Escitalopram and S-Demethylcitalopram in Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lactams</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>Adult healthy volunteers, aged 18 to 55 years, inclusive Body mass index (BMI) 18.0 to 32.0 kg, inclusive Absence of evidence of any active or chronic disease Nonsmokers Presence of any active or chronic disease Abnormal blood pressure Abnormal resting heart rate Abnormal ECG values History of any clinically significant cardiovascular or cerebrovascular disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>